ALS TDI -The First Non Profit Biotech, A Hidden Investment Opportunity?

Strategically, the organization has done a good job in moving drugs through clinical trials but lacks venture capital funding. But the benefit investors stand to gain is a major stakehold in the drug with a low investment.

Read more »

TDI-132 shows promising results in the treatment of ALS

ALS may be the most deadly disease many people have never heard of. Also referred to as Lou Gehrig’s disease, it affects at least 30,000 people in the United States and 450,000 people worldwide.

Read more »

Cytokinetics Receives Orphan Drug Status for ALS Treatment

Promising data from a Phase I clinical trial of CK-2017357 was announced in January.

Read more »

Cellular Reprogramming May Offer Stem-Cell Compromise

President Obama’s recent reversal of Bush’s policy on embryonic stem cell research reignited the debate over the ethical limits of science. However, as the Wall Street Journal reports, an innovative new technique could potentially reproduce the benefits of embryonic stem cells without the attendant controversy.

Read more »